Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
KNTEDelisted Stock | USD 2.96 0.27 8.36% |
About 61% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
Kinnate |
SAN FRANCISCO and SAN DIEGO, June 01, 2023 Kinnate Biopharma Inc. , a clinical-stage precision oncology company, today announced that the company will participate in two upcoming investor conferences Wednesday, June 7 at 230 p.m. ET 1130 a.m. PT at the Jefferies Healthcare Conference. Neha Krishnamohan, chief financial officer and executive vice president, corporate strategy, will represent the company in a fireside chat at the conference.Thursd
Read at finance.yahoo.com
Kinnate Biopharma Fundamental Analysis
We analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Kinnate Biopharma is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Kinnate Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kinnate Biopharma stock to make a market-neutral strategy. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics with similar companies.
Peers
Kinnate Biopharma Related Equities
KRON | Kronos Bio | 2.17 | ||||
BOLT | Bolt Biotherapeutics | 1.96 | ||||
PASG | Passage Bio | 1.54 | ||||
LRMR | Larimar Therapeutics | 1.00 | ||||
STOK | Stoke Therapeutics | 1.60 | ||||
SLRN | ACELYRIN, INC | 2.11 | ||||
GLUE | Monte Rosa | 2.22 | ||||
KROS | Keros Therapeutics | 2.32 | ||||
KZR | Kezar Life | 2.92 | ||||
ERAS | Erasca | 3.05 | ||||
EWTX | Edgewise Therapeutics | 3.10 | ||||
WINT | Windtree Therapeutics | 3.13 | ||||
GBIO | Generation Bio | 3.60 | ||||
DSGN | Design Therapeutics | 3.70 | ||||
IPSC | Century Therapeutics | 3.70 | ||||
CCCC | C4 Therapeutics | 5.25 | ||||
PALI | Palisade Bio | 5.65 | ||||
SRZN | Surrozen | 5.95 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Transaction History View history of all your transactions and understand their impact on performance | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
CEOs Directory Screen CEOs from public companies around the world | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |